Drug-labels.com

Myrbetriq: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
25 mg, 50 mg
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Myrbetriq

ABOUT THIS MEDICATION

What the medication is used for:

MYRBETRIQ treats the symptoms of an overactive bladder such as:

  • suddenly needing to empty your bladder (called urgency)
  • having to empty your bladder more than usual (called urinary frequency)
  • not being able to control when you empty your bladder (called urgency incontinence)

What it does:

MYRBETRIQ contains mirabegron. It works by relaxing the bladder smooth muscle, thereby reducing the symptoms of an overactive bladder.

When it should not be used:

  • you have very high uncontrolled blood pressure
  • if you are allergic to mirabegron or any of the ingredients in MYRBETRIQ
  • women who are pregnant or breastfeeding

What the medicinal ingredient is:

Mirabegron

What the nonmedicinal ingredients are:

butylated hydroxytoluene, hydroxypropyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, polyethylene oxide, yellow ferric oxide and red ferric oxide (25 mg only).

What dosage forms it comes in:

Extended-release tablets, 25 mg, 50 mg

WARNINGS AND PRECAUTIONS

BEFORE you use MYRBETRIQ talk to your doctor or pharmacist if:

  • you have problems emptying your bladder or if you have weak urine stream
  • you are pregnant or trying to become pregnant
  • you are breastfeeding or planning to breastfeed
  • you have severe liver problems
  • you have severe kidney problems
  • you have an eye problem called Glaucoma
  • you have high blood pressure or a history of high blood pressure

    • you have any heart disorder, including an irregular heartbeat, an abnormal electrical signal called “prolongation of the QT interval” or a known history of QT interval prolongation
    • you have a history of ischemic heart disease or a heart rate that is higher than normal

MYRBETRIQ should not be given to patients under 18 years of age.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. MYRBETRIQ may affect the way other medicines work, and other medicines may affect how

MYRBETRIQ works. You may need to change the dosage or stop taking one of the medicines.

MYRBETRIQ may interact with the following medications:

  • Propafenone, or Flecainide, drugs used to treat irregular heartbeats
  • Digoxin
  • Drugs known to increase the heartbeat or elevate blood pressure
  • Drugs known to prolong the QT/QTc interval and/or cause torsade de pointes

PROPER USE OF THIS MEDICATION

Usual starting dose:

25 mg once daily with or without food. The tablet should be swallowed whole with a glass of water. Do not crush or chew the tablet. Based upon your response and tolerability, your doctor may increase your dose to 50 mg once daily. The maximum dose for MYRBETRIQ is 50 mg once daily.

Overdose:

In case of drug overdose, contact your doctor, or a poison control centre, or go to emergency room of the hospital near you immediately, even if there are no symptoms.

Missed Dose:

If you forget to take your medicine, then take your next dose at the normal time. Do not take a double dose to make up for a forgotten dose. If you miss several doses, tell your doctor and follow the advice given to you.

MYRBETRIQ® Product Monograph Page 40 of 40

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

As with all medications, MYRBETRIQ can cause side effects. The possible common side effects are as follows:

  • Increased blood pressure
  • Cold symptoms (Nasopharyngitis)
  • Urinary tract infection
  • Constipation
  • Diarrhea
  • Dizziness
  • Headache
  • Nausea
  • Itching
SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effectTalk with your doctor or pharmacistStop taking drug and call your doctor or pharmacist
Only if severeIn all cases
Uncommon

Rash / Urticaria

(hives)

Urinary Retention

(the inability to empty your bladder)

Atrial fibrillation (rapid and irregular heart beat)

Cerebrovascular accident (stroke)

✓

✓

✓

✓

RareAngioedema (swelling of the face or tongue, difficulty breathing)✓

This is not a complete list of side effects. For any unexpected effects while taking MYRBETRIQ, contact your doctor or pharmacist.

HOW TO STORE IT

Keep out of the reach and sight of children. Store at 25oC (77oF) with excursions permitted from 15oC to 30oC (59oF to 86oF).

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

--------------------------------------------------------------------------

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Canada Vigilance Reporting Form and:

    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program

      Health Canada

      Postal Locator 0701D

      Ottawa, Ontario

      K1A 0K9

Postage-paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:

http://www.astellas.ca

or by contacting the sponsor, Astellas Pharma Canada, Inc., at:

1-888-338-1824

Last revised: June 02, 2016

16A007-MIR-CAN

MYRBETRIQ® is a registered trademark of Astellas Pharma Inc.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02402874

Revision date stated in the text: June 2, 2016

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Myrbetriq

Rx or OTC
Prescription (Rx)?
DIN 02402874, 02402882
Schedule(s) PRESCRIPTION
Active ingredient(s) Mirabegron
Dosage form(s) Tablet (Extended-Release)
Route(s) of administration Oral
Company ASTELLAS PHARMA CANADA INC
Current status Marketed
Current status date March 28, 2013
Strengths and forms
DIN Strength Dosage form(s) Current status
02402874 25 MG Tablet (Extended-Release) Marketed March 28, 2013
02402882 50 MG Tablet (Extended-Release) Marketed March 28, 2013

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.